Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 16/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 16/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 16/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 16/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 16/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 16/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 16/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 16/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13749942 | 0.87 | SRC (0.52) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4289349 | 0.86 | EGFR (0.62) | KDREGFRAURKB | |
| SCHEMBL3490157 | 0.85 | AURKA (0.57) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12342162 | 0.85 | KDR (0.52) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4286470 | 0.84 | AURKA (0.57) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4293774 | 0.83 | KDR (0.62) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6495649 | 0.83 | KDR (0.49) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4276684 | 0.83 | KDR (0.50) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3490057 | 0.83 | AURKA (0.64) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13749938 | 0.82 | SRC (0.58) | KDRHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567358-B2 | Methods of treatment using N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide | ASTRAZENECA AB (SE) | 2017-02-14 | — | — | US | disclosed |
| US-20150307534-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-29 | — | — | US | disclosed |
| US-9018191-B2 | Phosphonoxy quinazoline derivatives and their pharmaceutical use | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2014-06-12 | — | — | US | disclosed |
| US-8268841-B2 | Phosphonoxy quinazoline derivatives and their pharmaceutical use | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| US-20100069412-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | disclosed |
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-7402585-B2 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7402585-B2 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| EP-1847539-A1 | Quinazoline derivatives | AstraZeneca AB (SE) | 2007-10-24 | — | — | EP | disclosed |
| EP-1578755-B1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2007-08-22 | — | — | EP | disclosed |
| US-20060116357-A1 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
| EP-1578755-A1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
| EP-1463506-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | Astrazeneca AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004058781-A1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| WO-2003055491-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | PLK2, ABL1, CYP3A5 | KDR 2145/4885HDAC3 1721/4885HDAC4 2605/4885 |
| US-20150307534-A1 | CHEMICAL COMPOUNDS | ABL1, NQO1, NQO2 | KDR 1513/4885HDAC3 546/4885HDAC4 1692/4885 |
| US-20100069412-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | PLK2, ABL1, CYP3A5 | KDR 2145/4885HDAC3 1721/4885HDAC4 2605/4885 |
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | AURKC, AURKA, AURKB | KDR 933/4885HDAC3 1090/4885HDAC4 911/4885 |
| US-20060116357-A1 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | AURKA, AURKC, AURKB | KDR 642/4885HDAC3 734/4885HDAC4 798/4885 |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | AURKC, AURKA, AURKB | KDR 960/4885HDAC3 870/4885HDAC4 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.